At Merck, a proprietary library of roughly one million drug-like compounds is screened in 10-15 high-throughput screening (HTS) campaigns per year. Respective assays range from simple binding analysis to complex phenotypic assays with multiple read-out parameters. In order to understand the molecular mode of action (mMoA) of compounds as early as possible in the drug identification process, Merck also implement mMoA assays, such as competition assays or jump dilution assays into the HTS campaigns. Furthermore, selectivity and interference assays complement each HTS run to sort out false positives and promiscuous compounds on the fly.

Thus, each HTS campaign demands the development of multiple robust and high-quality assays in a very short timeframe. The DragonFly Discovery allows for the significant automation of such activities and using this flexible benchtop system, Merck were able to speed up assay development, multiplex assays, and save reagents. Furthermore, Merck could reduce miniaturization efforts by directly developing assays on 1536-well plates. In this webinar, Dr. Nina Grossmann and Adrian Schoen of Discovery Pharmacology at Merck, Darmstadt, will explore how they use the DragonFly Discovery to quickly set up robust high-throughput assays.

Join this webinar to learn about:

• Assay development for high-throughput screening (HTS)
• Molecular mode of action (mMoA) studies
• Routine lab assays in 1536-well formats

Who should attend:

• Technicians, lab managers, and scientists who are working in small-molecule drug discovery
• Scientists and researchers working in screening
• Those who want to speed up assay development for screening and mMoA studies